Summary We examined 46 non-small-cell lung carcinomas (NSCLCs) for the presence of p53 mutations in exons 4-9, positive p53 immunostaining and loss of heterozygosity (LOH) in the TP53 locus. p53 mutations were detected in 13 tumour samples (28.3%), whereas overexpression of the p53 protein was found in 30 of 45 (67%) samples. Allelic loss was found in 9 of 38 (23.6%) informative cases. The statistical analysis revealed no significant correlation between p53 mutations and clinicopathological data, although mutations appear to occur more frequently in squamous cell carcinomas (7 of 18) than in adenocarcinomas (2 of 15). All but three individuals in this study group smoked. In contrast to previous reports, we found a higher prevalence of GC-AT transitions than of GC-TA transversions, as expected in a smoking population. A trend was found between p53-positive immunostaining and a history of heavy smoking (76-126 pack-years) and was inversely correlated with allelic deletion (LOH) at the TP53 locus. Eight of the 12 NSCLCs containing p53 mutations also had concomitant p53 overexpression, and it is of specific note that three of the four tumours containing p53 'mutations' with no overexpression of the p53 protein had either insertions or deletions in the p53 gene. No correlation was found between p53 mutations and fractional allele loss or ras mutations. p53 mutations in this Merseyside population in the UK do not appear to be as common as in other reports for NSCLC and exhibit predominance of GC-AT transitions preferentially at non-CpG sites, suggesting that other carcinogens in addition to those in tobacco smoke may be involved in NSCLC in the Merseyside area of the UK.
Lung cancer is one of the major causes of death in the Western world. Small-cell lung carcinomas (SCLC) account for approximately 25% of all lung tumours and non-small-cell carcinomas (NSCLCs) constitute the remaining 75% (Whitehouse, 1994) . Lung cancer development is strongly related to environmental agents, and smoking appears to be responsible for the majority of the cases. Lung cancer is considered to be the major cause of death among smokers in the United States (Shopland et al, 1991) . Cigarette smoke contains a number of carcinogens, such as benzo- [a] pyrene, which may act in the initiation and/or promotion of the disease (DeMarini, 1983) .
During the last decade, a number of the known oncogenes and tumour-suppressor genes have been shown to be altered in lung tumours (Field et al, 1994) . The p53 gene encodes for a 53-kDa nuclear phosphoprotein which functions as a transcription factor and it is implicated in the regulation of the cell cycle and subsequently in growth control. p53 acts as a tumour-suppressor gene, arresting cells in the GIG1 phase whenever DNA is damaged to give more time for the cell's DNA repair mechanism to function, and, if unsuccessful, leads cells to apoptotic death (Levine et al, 199 1; Lane, 1992; Yin et al, 1992) .
The p53 gene has been found to be mutated in a large range of human tumours (Hollstein et al, 1991; Greenblatt et al, 1994;  Sidransky and Hollstein, 1996) . Many international research groups have contributed to the identification of p53 mutations and in a number of cases have correlated the presence ofp53 mutations with stage, histology, prognosis and exposure to certain environmental agents. Mutagens can produce specific base substitutions at certain sites, and a mutation spectrum analysis may provide information about the origins of mutations that give rise to human tumours. A recent review of the published data on p53 mutations in human tumours worldwide led to a number of hypotheses concerning the role ofp53 in carcinogenesis (Greenblatt et al, 1994 ).
Lung tumours have been shown to contain various genetic aberrations within the p53 gene, including point mutations, insertions, deletions and loss of heterozygosity at the TP53 locus (Chiba et al, 1990; Lehman et al, 1991; Sameshima et al, 1992; Mitsudomi et al, 1992 Mitsudomi et al, , 1993 Suzuki et al, 1992; Lohman et al, 1993; Takeshima et al, 1993; Westra et al, 1993; Carbone et al, 1994; Zheng et al, 1994) . With respect to point mutations, GC-.TA transversions have been shown to occur more frequently in smokers than in non-smokers with lung cancer and may be the result of specific carcinogenic agents present in tobacco smoke, such as benzo-[a]pyrene (Greenblatt et al, 1994; Husgafuel-Pursianen et al, 1995; Ramet et al, 1995) .
In the present study, we have examined p53 status in 46 patients with NSCLC for the presence of mutations in exons 4-9, expression of the p53 gene and allelic loss in the TP53 locus. All patients live within Merseyside, UK, where the incidence of the disease is Youngson and Williams, 1995 among the highest in Europe, especially in women (Williams, 1992 
DNA extraction and PCR
Tumour tissues were microdissected before DNA extraction, which was undertaken with Nucleon II (Scotlab, Coatbridge, UK). The oligonucleotides used for the polymerase chain reaction (PCR) amplification of the p53 exons and the thermal profile of the amplification have been described previously (Lehman et al, 1991 (Field et al, 1995 Neville et al, 1996) .
Statistical analysis
In order to find any correlations between the presence of mutations and the clinicopathological data, the Fisher's exact test was employed, using the SAS software for PCs. On examining the 11 base substitutions, one was silent, two nonsense and eight missense. The 1-bp deletion led to a frameshift, resulting in a stop codon 12 amino acids after the deletion point; the 4-bp deletion led to a frameshift, again resulting in a stop codon 36 amino acids after the deletion point; the 19-bp deletion led to a truncation of six amino acids and a frameshift, which generated a stop codon 11 amino acids after the deletion point; and the 3-bp insertion led to a substitution of valine for histidine and the addition of a serine without producing any frameshift changes. The 1-bp insertion in patient no. 52 occurs in the intronic region 24 bp before the first nucleotide of exon 5 and does not appear to affect splicing.
Two of the tumours (patient nos. 18 and 52) were found to carry more than one mutation, and all multiple mutations occurred in British Journal of Cancer (1997) exon 5. In the case of patient no. 52, there was an additional 1-bp insertion in the intronic region, and the distance between the 1-bp deletion and the C-.T substitution within exon 5 was only four nucleotides. Statistical analysis showed no correlation between the presence of p53 mutations and the clinicopathological data, i.e. age, stage, TNM stage, nodes at pathology, alcohol intake, cigarettes and clinical outcome (follow-up 18 months). Samples from 4 of the 18 female patients and 9 of 28 male patients contained p53 mutations. However, p53 mutations occurred more frequently in squamous cell carcinomas (7 of 18) than in adenocarcinomas (2 of 15), but this was not statistically significant. Similarly, the presence of the minor allele (Pro) in codon 72 in exon 4, found in 6 out of 46 samples, did not correlate with any of the particular clinicopathological parameters.
The immunohistochemical study of the p53 protein revealed that 15 of 45 (33%) samples had negative (-) staining, 5 of 45 (11%) samples had weak positive (+) staining and 25 of 45 (56%) samples had intense positive (++ or +++) staining for p53. We divided the patients into three classes with respect to the number of cigarettes they consumed in pack-years: light smokers (0-45 pack-years); moderate smokers (46-67.5 pack-years); and heavy smokers (76-126 pack-years). A trend was found between p53-positive staining and the patients' smoking history; however, this was found to be not statistically significant (P = 0.13) ( Table 3 ).
In the 12 NSCLC specimens with p53 mutations for which we also had p53 expression data (Table 1) , eight had concomitant p53 mutation and p53-positive staining. However, it is noteworthy that three of the four tumours containing p53 mutations that had no p53-positive staining (patient nos. 21, 44 and 52) had mutations that result in truncation of the expressed protein. The fourth sample (patient no. 19) has an inframe 3-bp insertion that did not result in truncation, and so the reason for non-immunoreactivity remains unclear. It is of interest that patient no. 19 was the only non-smoker with a p53 mutation.
The TP53 LOH study indicated allelic loss in 9 of 38 (23.6%) of the informative cases. In the case of patient no. 34, microsatellite instability (MI) was observed at this locus. Statistical analysis showed no correlation between LOH and the clinicopathological parameters. However, an inverse correlation was found between LOH and staining for p53, indicating that overexpression of the p53 gene was uncommon in samples with LOH at the TP53 locus (P = 0.005).
In an extensive allelotype analysis of lung tumours, the fractional allele loss (FAL) value was calculated for the 46 tumours for which we had LOH data for 38 chromosome arms. The FAL value for this group of tumours was found to be 0.09. (FAL was calculated as the number of chromosome arms showing loss of heterozygosity divided by the number of informative chromosome arms; Field et al, 1996; Neville et al, 1996 .) We investigated whether there was a correlation between the presence of p53 mutations and the FAL value, but no statistically significant correlation was found. Furthermore, there was no correlation between p53 aberrations and K-ras mutations (Neville et al, 1995a) or allelic loss on chromosome 9 at 9p23, a site considered to contain a putative tumour-suppressor gene in these tumours (Neville et al, 1995b) . DISCUSSION p53 gene inactivation by mutation or allelic loss has been implicated in the development of lung cancer (Greenblatt et al, 1994) . The identification of mutations that arise within the gene may lead to an understanding of the role of the p53 gene in the development of lung tumours and may also help to elucidate the role of certain carcinogenic agents, e.g. those contained in tobacco or environmental pollutants, in this disease process. In this study, we found that 28% of the tumours contained mutations in the p53 gene. This incidence is significantly lower (P < 0.0002) than that reported in a major review ofp53 mutations in 897 lung cancer patients who have smoked (Greenblatt et al, 1994; Hollstein et al, 1994) . On comparing our results with those of Suzuki et al (1992) , who demonstrated p53 mutations in 47% of 30 NSCLCs investigated, no statistically significant difference was found (P = 0.082). The possibility that p53 mutations were missed by SSCP screening is very unlikely as SSCP-negative results were confirmed by sequencing 10 SSCP-negative samples per exon; however, even if we calculated that 10% of p53 mutations were missed, the total incidence would rise to only 31%, which is still lower than the average incidence of p53 mutations in lung cancer (56%), as reported by Greenblatt et al (1994) . Our results indicate that p53 mutations in NSCLC may be caused by carcinogens other than those found in tobacco smoke. This may account for the population-specific mutation spectrum.
Sixty-seven per cent of the NSCLC samples in this study demonstrated p53-positive staining. It is of note that all but one of the patients' tumours with p53 mutations, excluding those with insertions or deletions, also demonstrated p53-positive staining. This provides further evidence for the hypothesis that there is an increased p53 gene product in tumours containing mutations in the p53 gene. The p53-positive staining is considered to represent stable p53 protein overexpression that results from post-translational modification and/or p53 protein complexing. However, there were also NSCLC tumours that demonstrated p53-positive staining but in which no mutations were found. These differences British Journal of Cancer (1997) 75(8), [1119] [1120] [1121] [1122] [1123] [1124] p53 aberrations in NSCLC 1123 between molecular and immunohistochemical results may be explained by the possibility that there are mutations in the p53 gene outside exons 4-9, within the p53 promoter region, or that overexpression of p53 is not only due to p53 mutations but also to some other factors, e.g. mdm2, which bind to the p53 protein and thus increase its half-life. Furthermore, it may be argued that the DO-1 antibody may also detect a stable conformationally altered wild-type p53 protein which, in its own right, may lead to genetic instability without an initial p53 mutation.
More than half (6 of 11) of base substitutions occur at G residues, which is in agreement with previous reports (Greenblatt et al, 1994) . However, in contrast with most previous reports, we found a higher prevalence of GC-.AT transitions (37.5% of all mutations) than of GC--TA transversions (12.5%), which would be expected from a smoking population. Comparison of the ratio of GC-TA to GC-*AT in this study and Greenblatt's review showed a significant difference (P = 0.04). Husgafvel-Pursiainen et al (1995) reviewed the mutational profile in smokers and exsmokers among lung cancer patients and found that 34% of p53 mutations were G-.T base substitutions. In this study, however, only 18% of the smokers had G-T transversions. Findings similar to our own were reported in NSCLC patients from Taiwan, in whom G-.T mutations constituted only 6% of p53 mutations detected in a population sample comprising 61% smokers (Lee et al, 1994) . GC-TA transversions have been attributed to the action of benzo [a] pyrene, a member of the polycyclic aromatic hydrocarbons, which represent the major carcinogens found in tobacco smoke. However, other carcinogens, such as 4-(methylnitrosamino)-1-(3-pyridyl)-l-butanone (NNK), cause GC-*AT transitions and GC-.TA transversions at CpG and non-CpG sites, depending on the experimental system used (Wynder and Hoffmann, 1994) . Tobacco smoke is a complex mixture of compounds, and the mutational spectrum it causes needs further investigation (DeMarini et al, 1995) . Hence, it remains unclear whether or not the prevalence of GC-.AT transitions found in the smoking population in this study is a paradox. It is possible that, rather than one factor acting alone, a combination of one or many environmental components and genetic factors may act synergistically.
Strikingly, in this study all four C-*T and one out of three G-.A mutations (five out of seven GC-.AT in total) occurred at nonCpG dinucleotides (in this case in CpC/GpG dinucleotides; Table 2 ). CpG sites can account for mutations due to spontaneous deamination of 5-methylcytosine residues, but the reason for the occurrence of GC-.AT transitions at non-CpG sites is unclear. As little is known about methylation at non-CpG sites in mammalian cells (Tasheva and Roufa 1994) , it is uncertain whether GC-.AT transitions at non-CpG sites represent induced or spontaneous mutagenesis (Yang et al, 1996) .
No correlation was found between the presence of mutations and the stage of tumour, indicating that p53 mutations may be considered to play a role in the early development of lung cancer. However, it may also be argued that cells containing p53 mutations could be harbouring a mutation in another gene that may merely have a selective growth advantage in vivo, and this would result in the late amplification of a p53-mutant subset of cells in a mixedstatus tumour cell population. The presence of only one 'nonsmoker' in our samples did not allow us to undertake any comparison of p53-positive staining and a history of smoking vs non-smoking; however, a trend was found between p53 immunostaining and a history of heavy smoking (76-126 pack-years) compared with light smoking (0-45 pack-years), but this was found to be not statistically significant (P = 0.13).
p53 mutations did not correlate with age, alcohol consumption or prognosis (median 18 months' follow-up). However, a trend was found between the prevalence ofp53 mutations and squamous carcinomas, which is in agreement with a previous report by Mitsudomi et al (1993) . The absence of a correlation between p53 mutations and various clinicopathological parameters indicates that a mutation in the p53 gene may not by itself lead to aggressive cell growth. Recently, an inverse correlation between clinical outcome and p53-positive immunostaining was found; however, no correlation was found between p53 mutations and survival (Carbone et al, 1994) . It is also probable that these tumours carry additional alterations in genes that function as oncogenes or tumour-suppressor genes; indeed, the allelotype study for this set of tumours showed a median FAL value of 0.09, indicating allelic imbalance throughout the genome . In particular, LOH at the TP53 locus, as shown in this study, was found in 25% of these tumours. It is of note that only two out of ten samples with LOH at TP53 were found to contain a mutation in p53, implying that another candidate tumour-suppressor gene may also exist at this locus. Additionally, four mutations in codon 12 of the K-ras gene have also been demonstrated in these tumours (Neville et al, 1995a) . Only one of the tumours was found to contain mutations in both the K-ras and the p53 genes.
In conclusion, p53 mutations in the population of the Merseyside region of the UK do not appear to be as common as in other reports of NSCLC. GC-.AT transitions in p53, preferentially occurring at non-CpG sites, suggest that different environmental carcinogens may be involved in this geographic area.
